Introduction {#sec1}
============

Rotator cuff disease is the most common etiology of shoulder pain, which leads to discomfort, pain and motor dysfunction \[[@B1]\]. Rotator cuff tear (RCT) is present in 20--54% of persons aged between 60 and 80 years \[[@B2],[@B3]\]. As the population ages, the prevalence of RCTs increases significantly \[[@B4]\]. There is evidence that metabolic disorders (diabetes, obesity, hypercholesterolemia), hypertension and cigarette smoking are risk factors for RCT development \[[@B5]\]. In addition to behavioral influences, familial and genetic factors that influence RCT development have also been identified \[[@B6]\].

Patients with full-thickness RCT have increased levels of synovial inflammation in comparison with healthy controls \[[@B7]\]. Interleukin (IL)-6 (IL-6), which is rapidly and transiently produced in response to infections and tissue injuries, contributes to host defense \[[@B8]\]. In patients with RCT, expression of IL-1, IL-6 and TNF-α in the subacromial bursa has been shown to be elevated in comparison with healthy controls \[[@B9]\]. Additionally, higher IL-1β and IL-6 levels were related to more severe pain in animal RCT models \[[@B10]\]. IL-6 expression levels are higher in ruptured Achilles tendon compared with normal Achilles tendon and painful Achilles tendon \[[@B11]\].

IL-6 is located on chromosome 7p15.3 and has six exons. *IL-6* gene variants have been studied in various diseases. However, little is known about their association with susceptibility to RCT. The rs1800795 (−174 G\>C) and rs1800797 (−597 A\>G) polymorphisms are located in the promoter region of *IL-6* gene, and these polymorphisms influence the production of IL-6 in plasma \[[@B12],[@B13]\]. As such, we performed a case--control study to evaluate the role of *IL-6* gene polymorphisms (rs1800795 and rs1800797) on the risk of RCT in a Chinese population. Additionally, the study also evaluated the association between IL-6 gene polymorphisms and clinical outcome of two management of RCT (operative vs. consevative).

Methods {#sec2}
=======

Study subjects {#sec2-1}
--------------

One hundred and thirty-eight patients were recruited for the present study and were screened with magnetic resonance imaging to confirm full-thickness supraspinatus or infraspinatus RCT at the Second Affiliated Hospital of Jiaxing University and The Second Affiliated Hospital, Zhejiang University School of Medicine between October 2015 and December 2018. Exclusion criteria included partial-thickness RCT, calcifying tendinitis, trauma or systemic disease, or any patient who had undergone a surgical procedure on the injured shoulder. The control group (matched for age and sex) consisted of individuals receiving a routine health examination at the same hospitals and without symptoms of shoulder pain and clinical signs of rotator cuff diseases. Participants with prior operations on their shoulder or a history of humeral fracture were excluded from the present study. All participants completed self-designed questionnaire forms (sex, age, drinking status, smoking status and body mass index (BMI)) that included medication use, personal history of rotator cuff disease and inflammatory disease.

The present study was approved by the Ethics Committee of the above two hospitals. All participants provided written informed consent prior to participation in the study.

DNA extraction and genotyping {#sec2-2}
-----------------------------

We extracted genomic DNA from 2 ml whole blood sample using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Optical density at 260/280 nm was measured to evaluate the quality of the extracted DNA. Genotyping was performed by polymerase chain reaction (PCR) and Sanger sequencing. The primers were: 5′-CTGGCAGCACAAGGCAAAC-3′ (rs1800797F) and 5′-AGGCAACTGGACCGAAGG-3′ (rs1800795R). PCR amplification was performed in a 25-µl reaction volume containing 200 μM dNTPs, 10× PCR buffer of 1.5 μM MgCl~2~, 1 U Taq polymerase, 100 ng genomic DNA and 20 pmol of each pair of primer and ddH~2~O. The PCR product was analyzed on 2% agarose gel electrophoresis with ethidium bromide and was then photographed. The purified PCR product was sequenced by GenScript Inc. (Nanjing, China). Genotyping on a random selection (3%) of samples was repeated in a blind manner for quality control, and the results were 100% concordant.

Enzyme-linked immunosorbent assay {#sec2-3}
---------------------------------

Shoulder joint synovial fluid was collected from RCT patients. The collected synovial fluid was centrifuged and the supernatants were stored at −80°C until use. The IL-6 levels were determined using the human IL-6 enzyme-linked immunosorbent assay (ELISA) Kit (Sino Biological, Beijing, China) following manufacturer's recommendations. The IL-6 level was calculated by interpolation from a standard curve.

Outcome assessment {#sec2-4}
------------------

We divided RCT patients into two groups: surgical and conservative groups. The patients from surgical group was diagnosed with RCT through magnetic resonance imaging. Conservative management includes nonsteroidal anti-inflammatory drugs, physiotherapy and rest. Patients' injured shoulder had not previously undergone surgery. We evaluate the clinical outcome at baseline, 6 and 12 months after surgical group and at inclusion for the conservative group. The clinical outcome was evaluated by constant score and visual analog scale (VAS). The constant score includes shoulder function test (65 points) and patients' subjective assessment (35 points). The pain and disability were determined with VAS. The score varies from 0 to 9, and higher scores indicate higher levels of pain and disability.

Statistical analyses {#sec2-5}
--------------------

A Student's *t* test or χ^2^ test was used to assess differences in mean and frequency distributions of demographic and clinical characteristics among cases and controls. We calculated the odds ratios (ORs) and 95% confidence intervals (CIs) to evaluate the association between IL-6 gene polymorphisms and risk of RCT by logistic regression analyses, and adjusted for sex and age. A goodness-of-fit chi-squared test was used to test the departure from Hardy--Weinberg equilibrium (HWE) of IL-6 genotype distributions in controls. All statistical analyses were performed using SAS (var. 9.1.3; SAS Institute, Cary, NC, U.S.A.). *P*\<0.05 was considered to indicate statistical significance.

Results {#sec3}
=======

Characteristics of the study population {#sec3-1}
---------------------------------------

One hundred and thirty-eight RCT patients and 137 healthy controls were recruited in the present study. The average age of the RCT patients was 52.66 years compared with 53.12 years for the controls (*P*=0.128). There was no significant difference between the two groups with regard to sex, smoking status, alcohol consumption, BMI. We also recorded family history of RCT and tear size of RCT patients to investigate its association with IL-6 rs1800795/rs1800797 polymorphisms ([Table 1](#T1){ref-type="table"}).

###### The demographics and risk factors of study population

  Characteristics           Case (*n*=138)   Control (*n*=137)   *P*
  ------------------------- ---------------- ------------------- -------
  Age, years                52.66 ± 10.98    53.12 ± 11.05       0.731
  Sex                                                            0.184
    Male                    75 (54.3%)       64 (46.7%)          
    Female                  63 (45.7%)       73 (53.3%)          
  BMI, kg/m^2^              25.87 ± 3.18     25.99 ± 3.21        0.757
  Smoking                                                        0.763
    Yes                     68 (49.3%)       70 (51.1%)          
    No                      70 (50.7%)       67 (48.9%)          
  Alcohol                                                        0.764
    Yes                     66 (47.8%)       68 (49.6%)          
    No                      72 (51.2%)       69 (50.4%)          
  Affected side                                                  
    Right                   80 (58.0%)                           
    Left                    58 (42.0%)                           
  Family history of RCT                                          
    Yes                     11 (8.0%)                            
    No                      127 (92.0%)                          
  Tear size                                                      
    Small                   71 (51.4%)                           
    Medium                  41 (29.7%)                           
    Large                   26 (18.8%)                           
  Pre-operative stiffness                                        
    Yes                     38 (27.5%)                           
    No                      100 (72.5%)                          

Quantitative analysis {#sec3-2}
---------------------

The genotype distributions of *IL-6* gene polymorphisms among cases and controls are shown in [Table 2](#T2){ref-type="table"}. No significant deviation from HWE was found for rs1800795/rs1800797 polymorphisms in both cases and controls, suggesting these subjects are representative of the local population. The *IL-6* rs1800795 polymorphism was significantly associated with an increased risk of RCT under the homozygous and allelic models. Moreover, the GG or GG+AG genotype of *IL-6* rs1800797 polymorphism showed significant correlation with risk of RCT compared with AA genotype (GG vs. AA; OR, 2.29; 95% CI, 1.11--4.72; *P*=0.025; GG+AG vs. AA; OR, 1.69; 95% CI, 1.03--2.79; *P*=0.040). The *IL-6* rs1800797 polymorphism demonstrated significant association with risk of RCT under the allelic model. After adjusting for sex age and BMI, these findings remained significant.

###### Genotype frequencies of IL-6 gene polymorphisms in cases and controls

  Models         Genotype   Case (*n*, %)   Control (*n*, %)   OR (95% CI)             *P*-value   [\*](#T2TFN1){ref-type="table-fn"}OR (95% CI)   [\*](#T2TFN1){ref-type="table-fn"}*P*-value
  -------------- ---------- --------------- ------------------ ----------------------- ----------- ----------------------------------------------- ---------------------------------------------
  rs1800795                                                                                                                                        
  Wild           CC         39 (28.5%)      54 (39.7%)         1.00 (reference)        *-*         1.00 (reference)                                \-
  Heterozygote   CG         69 (50.4%)      64 (47.1%)         1.49 (0.88--2.55)       0.141       1.48 (0.86--2.54)                               0.155
  Homozygote     GG         29 (21.2%)      18 (13.2%)         **2.23 (1.09--4.57)**   **0.029**   **2.10 (1.01--4.33)**                           **0.046**
  Dominant       CC         39 (28.5%)      54 (39.7%)         1.00 (reference)        \-          1.00 (reference)                                \-
                 GG+CG      98 (71.5%)      82 (60.3%)         1.66 (0.99--2.74)       0.051       1.62 (0.97--2.70)                               0.066
  Recessive      CG+CC      108 (78.8%)     118 (86.8%)        1.00 (reference)                    1.00 (reference)                                \-
                 GG         29 (21.2%)      18 (13.2%)         1.76 (0.93--3.35)       0.085       1.66 (0.87--3.19)                               0.126
  Allele         C          147 (53.6%)     172 (63.2%)        1.00 (reference)        \-          1.00 (reference)                                \-
                 G          127 (46.4%)     100 (36.8%)        **1.49 (1.06--2.09)**   **0.023**   \-                                              *-*
  rs1800797                                                                                                                                        
  Wild           AA         41 (29.9%)      57 (41.9%)         1.00 (reference)        \-          1.00 (reference)                                \-
  Heterozygote   AG         68 (49.6%)      62 (45.6%)         1.53 (0.90--2.59)       0.118       1.56 (0.91--2.66)                               0.104
  Homozygote     GG         28 (20.4%)      17 (12.5%)         **2.29 (1.11--4.72)**   **0.025**   **2.29 (1.10--4.77)**                           **0.026**
  Dominant       AA         41 (29.9%)      57 (41.9%)         1.00 (reference)        \-          1.00 (reference)                                \-
                 GG+AG      96 (70.1%)      79 (58.1%)         **1.69 (1.03--2.79)**   **0.040**   **1.72 (1.04--2.85)**                           **0.036**
  Recessive      AG+AA      109 (79.6%)     119 (87.5%)        1.00 (reference)        \-          1.00 (reference)                                \-
                 GG         28 (20.4%)      17 (12.5%)         1.80 (0.93--3.47)       0.080       1.78 (0.92--3.47)                               0.089
  Allele         A          150 (54.7%)     176 (64.7%)        1.00 (reference)        \-          1.00 (reference)                                \-
                 G          124 (45.3%)     96 (35.3%)         **1.52 (1.07--2.14)**   **0.018**   \-                                              **-**

The genotyping was successful in 137 cases and 136 controls for rs1800795; the genotyping was successful in 137 cases and 136 controls for rs1800797. Bold values are statistically significant (*P*\<0.05).

Adjusted for age, sex and BMI.

We performed subgroup analyses according to sex, smoking status, alcohol consumption, ageand BMI ([Table 3](#T3){ref-type="table"}). For rs1800795, there were no significant differences in the frequencies of genotypes and alleles for the rs1800795 polymorphism between these groups. However, we found a significant positive association between *IL-6* rs1800797 polymorphism and RCT risk among women and drinkers in the homozygous model. This significant association was also evident in subgroups of subjects with BMI \< 25 kg/m^2^.

###### Stratified analyses between rs1800795/rs1800797 polymorphisms and the risk of RCT

  Variable        Case/control   Heterozygous   Homozygous   Recessive                  Dominant                                               
  --------------- -------------- -------------- ------------ -------------------------- --------------------------- -------------------------- --------------------------
  rs1800795                                                                                                                                    
  Sex                                                                                                                                          
    Male          20/26          36/27          18/10        1.73 (0.81--3.73); 0.160   2.34 (0.89--6.16); 0.085    1.70 (0.72--4.02); 0.224   1.90 (0.93--3.89); 0.080
    Female        19/28          33/37          11/8         1.31 (0.62--2.78); 0.474   2.03 (0.69--5.97); 0.200    1.72 (0.64--4.58); 0.279   1.44 (0.70--2.95); 0.317
  Smoking                                                                                                                                      
    Yes           22/30          36/33          9/7          1.49 (0.72--3.07); 0.283   1.76 (0.57--5.43); 0.330    1.40 (0.49--3.99); 0.533   1.53 (0.77--3.08); 0.228
    No            17/24          33/31          20/11        1.50 (0.68--3.32); 0.313   2.57 (0.98--6.72); 0.055    2.00 (0.87--4.58); 0.102   1.78 (0.85--3.74); 0.127
  Alcohol                                                                                                                                      
    Yes           20/28          35/34          10/6         1.44 (0.69--3.03); 0.335   2.33 (0.73--7.47); 0.154    1.88 (0.64--5.51); 0.250   1.58 (0.77--3.22); 0.213
    No            19/26          34/30          19/12        1.55 (0.72--3.35); 0.263   2.17 (0.85--5.51); 0.105    1.67 (0.74--3.78); 0.216   1.73 (0.84--3.54); 0.135
  Age (years)                                                                                                                                  
    \<60          29/37          51/42          19/13        1.55 (0.82--2.92); 0.177   1.87 (0.79--4.39); 0.154    1.44 (0.67--3.12); 0.351   1.62 (0.89--2.96); 0.114
    ≥60           10/17          18/22          10/5         1.39 (0.51--3.78); 0.517   3.40 (0.90--12.82); 0.071   2.79 (0.86--9.05); 0.088   1.76 (0.69--4.53); 0.239
  BMI (kg/m^2^)                                                                                                                                
    \<25          15/21          33/20          13/9         2.20 (0.92, 5.25); 0.076   1.93 (0.65, 5.68); 0.235    1.20 (0.47, 3.11); 0.701   2.12 (0.94, 4.78); 0.072
    ≥25           24/33          36/44          16/25        1.13 (0.57, 2.23); 0.736   2.44 (0.93, 6.46); 0.071    2.28 (0.94, 5.52); 0.067   1.35 (0.70, 2.59); 0.367

  Variable        case/control   Heterozygous   Homozygous   Recessive                  Dominant                                               
  --------------- -------------- -------------- ------------ -------------------------- --------------------------- -------------------------- --------------------------
  rs1800797                                                                                                                                    
  Sex                                                                                                                                          
    Male          25/25          34/30          15/9         1.13 (0.54--2.38); 0.740   1.67 (0.62--4.51); 0.314    1.55 (0.63--3.84); 0.340   1.26 (0.63--2.52); 0.520
    Female        16/32          34/32          13/8         2.13 (0.98--4.59); 0.055   3.25 (1.12--9.43); 0.030    2.08 (0.80--5.41); 0.133   2.35 (1.13--4.89); 0.022
  Smoking                                                                                                                                      
    Yes           18/25          36/36          14/9         1.39 (0.65--2.98); 0.398   2.16 (0.77--6.07); 0.144    1.76 (0.71--4.38); 0.227   1.54 (0.75--3.19); 0.243
    No            23/32          32/26          14/8         1.71 (0.81--3.61); 0.157   2.44 (0.88--6.76); 0.088    1.85 (0.72--4.74); 0.203   1.88 (0.94--3.77); 0.075
  Alcohol                                                                                                                                      
    Yes           15/26          32/33          15/9         1.89 (0.86--4.17); 0.115   2.89 (1.02--8.19); 0.046    1.93 (0.78--4.78); 0.156   2.11 (0.99--4.48); 0.054
    No            26/31          36/29          13/8         1.32 (0.64--2.71); 0.458   1.94 (0.70--5.39); 0.205    1.68 (0.65--4.35); 0.285   1.45 (0.74--2.86); 0.283
  Age (years)                                                                                                                                  
    \<60          32/37          49/44          18/10        1.29 (0.69--2.40); 0.427   2.08 (0.84--5.15); 0.113    1.80 (0.78--4.14); 0.166   1.44 (0.79--2.60); 0.233
    ≥60           9/20           19/18          10/7         2.35 (0.85--6.49); 0.101   3.17 (0.91--11.03); 0.069   1.94 (0.66--5.72); 0.231   2.58 (0.99--6.67); 0.051
  BMI (kg/m^2^)                                                                                                                                
    \<25          15/23          32/20          15/6         2.58 (1.09, 6.12); 0.031   3.83 (1.22, 12.09); 0.021   2.23 (0.79, 6.28); 0.128   2.88 (1.28, 6.49); 0.011
    ≥25           26/34          36/42          13/11        1.12 (0.57, 2.21); 0.741   1.55 (0.60, 4.00); 0.370    1.45 (0.61, 3.46); 0.404   1.21 (0.64, 2.30); 0.562

Bold values are statistically significant (*P*\<0.05).

Most clinical characteristics of RCT patients did not demonstrate and significant association with the *IL-6* rs1800795 polymorphism ([Table 4](#T4){ref-type="table"}). However, the GG genotype of rs1800795 polymorphism was more frequent in patients with large tear size compared with patients with medium tear size, suggesting an association with tear size of RCT patients. Additionally, we observed no evidence of a significant association between rs1800797 polymorphism and clinical characteristics of RCT.

###### The associations between IL-6 rs1800795/rs1800797 polymorphisms and clinical characteristics of RCT

  Characteristics            Genotype distributions                                                               
  -------------------------- ------------------------ --------------------------- ------------------------------- ---------------------------
  rs1800795                                                                                                       
  Tear size                                                                                                       
    Large/Medium             4/15                     12/21                       10/5                            14/26
    OR (95% CI); *P*-value   1.0 (reference)          2.14 (0.58--7.95); 0.255    **7.50 (1.61--34.95); 0.010**   2.02 (0.56--7.26); 0.282
  Tear size                                                                                                       
    Large/Small              4/20                     12/36                       10/14                           22/50
    OR (95% CI); *P*-value   1.0 (reference)          1.67 (0.47--5.86); 0.426    3.57 (0.93--13.72); 0.064       2.20 (0.67--7.19); 0.192
  Family history                                                                                                  
    Yes/No                   1/38                     8/61                        2/27                            10/88
    OR (95% CI); *P*-value   1.0 (reference)          4.98 (0.60--41.43); 0.137   2.82 (0.24--32.64); 0.408       4.32 (0.53--34.93); 0.170

  Characteristics            Genotype distributions                                                           
  -------------------------- ------------------------ --------------------------- --------------------------- ---------------------------
  rs1800797                                                                                                   
  Tear size                                                                                                   
    Large/Medium             4/12                     16/18                       5/11                        21/29
    OR (95% CI); *P*-value   1.0 (reference)          2.67 (0.72--9.95); 0.144    1.36 (0.29--6.42); 0.695    2.17 (0.61--7.68); 0.229
  Tear size                                                                                                   
    Large/Small              4/25                     16/34                       5/12                        21/46
    OR (95% CI); *P*-value   1.0 (reference)          2.94 (0.88--9.88); 0.081    2.60 (0.59--11.49); 0.206   2.85 (0.88--9.24); 0.080
  Family history                                                                                              
    Yes/No                   1/40                     6/62                        4/24                        10/86
    OR (95% CI); *P*-value   1.0 (reference)          3.87 (0.45--33.37); 0.218   6.67 (0.70--63.19); 0.098   4.65 (0.58--37.59); 0.149

Bold values are statistically significant (*P*\<0.05).

IL-6 expression in shoulder joint synovial fluid {#sec3-3}
------------------------------------------------

We further investigated the effect of IL-6 gene polymorphism on the IL-6 expression using ELISA method. There is a significant difference among three genotypes of rs1800795/rs1800797 polymorphism with regard to the IL-6 levels ([Figure 1](#F1){ref-type="fig"}). The mutant/heterozygous genotype had a higher IL-6 levels had a significantly higher expression of IL-6 in shoulder joint synovial fluid than wild genotype.

![The IL-6 expression among three genotypes\
(**A**) rs1800795; (**B**) rs1800797.\**P*\<0.05; \*\**P*\<0.01.](bsr-40-bsr20200193-g1){#F1}

Outcome {#sec3-4}
-------

A majority of RCT patients chose surgical treatment rather than conservative treatment ([Table 5](#T5){ref-type="table"}). No significant difference was observed among two groups with regard to age, sex, drinking, affected side, family history of RCT and tear size. Remarkably, the mean BMI and proportion of smokers differ significantly among two groups.

###### The functional baseline characteristics of patients with RCT

  Variables                       Surgery group (*n*=89)   Conservative group (*n*=49)   *P*
  ------------------------------- ------------------------ ----------------------------- -------------
  Age, years                      53.34 ± 10.69            51.43 ± 11.50                 0.330
  Sex                                                                                    0.895
    Male                          48 (53.9%)               27 (55.1)                     
    Female                        41 (46.1%)               22 (44.9)                     
  BMI, kg/m^2^                    25.45 ± 3.13             26.64 ± 3.16                  **0.037**
  Smoking                                                                                **0.037**
    Yes                           38 (42.7%)               30 (61.2%)                    
    No                            51 (57.3%)               19 (38.8%)                    
  Alcohol                                                                                0.104
    Yes                           38 (42.7%)               28 (57.1%)                    
    No                            51 (57.3%)               21 (42.9%)                    
  Affected side                                                                          0.830
    Right                         51 (57.3%)               29 (59.2%)                    
    Left                          38 (42.7%)               20 (40.8%)                    
  Family history of RCT                                                                  0.211
    Yes                           9 (10.1%)                2 (4.1%)                      
    No                            80 (89.9%)               47 (95.9%)                    
  Tear size                                                                              0.263
    Small                         42 (47.2%)               29 (59.2%)                    
    Medium                        27 (30.3%)               14 (28.6%)                    
    Large                         20 (22.5%)               6 (12.2%)                     
  Constant score (range 0--100)                                                          
    Baseline                      36.94 ± 3.44             37.93 ± 3.40                  0.107
    6 months                      66.05 ± 3.79             64.71 ± 3.28                  **0.042**
    12 months                     81.90 ± 3.77             77.81 ± 2.49                  **\<0.001**
  VAS score (range 0--10)                                                                
    Baseline                      6.74 ± 0.44              6.56 ± 0.38                   **0.017**
    6 months                      2.62 ± 0.31              3.30 ± 0.38                   **\<0.001**
    12 months                     1.09 ± 0.37              2.76 ± 0.44                   **\<0.001**

Bold values are statistically significant (*P*\<0.05).

[Table 5](#T5){ref-type="table"} also presents the follow-up results of RCT patients with/without surgery treatment. There was no significant difference in baseline constant score between surgery and conservative groups. The constant score of the surgery group was significantly higher than that of the conservation group (*P*\<0.05) after 6 months or 1 year of treatment. The primary VAS in the surgery group was higher, but decreased significantly after surgery treatment. Above all, the surgical treatment was significantly better than conservation treatment through evaluating constant score and VAS.

The present study also assessed whether IL-6 gene polymorphism is associated with the clinical outcome of RCT patients receiving surgery treatment ([Table 6](#T6){ref-type="table"}). The basic constant score in three genotypes of rs1800795 polymorphism did not differ significantly. Notably, CG genotype of rs1800795 polymorphism has the highest constant score compared with CC or GG genotype at 6 months (*P*\<0.05), indicating the significant association between IL-6 rs1800795 polymorphism. However, the finding is not applicable to rs1800797 polymorphism.

###### The association between IL-6 gene polymorphisms and functional outcome of surgery group at 1 year follow-up

  Outcome                         Genotype       *P*                           
  ------------------------------- -------------- -------------- -------------- -----------
  **rs1800795**                                                                
  Constant score (range 0--100)                                                
    Baseline                      37.03 ± 3.97   36.69 ± 3.23   37.36 ± 3.54   0.764
    6 months                      64.35 ± 3.03   67.02 ± 3.82   65.82 ± 3.80   **0.023**
    12 months                     81.06 ± 3.58   82.22 ± 3.89   82.27 ± 3.64   0.463
  VAS score (range 0--10)                                                      
    Baseline                      6.77 ± 0.50    6.66 ± 0.40    6.88 ± 0.43    0.170
    6 months                      2.55 ± 0.32    2.64 ± 0.32    2.63 ± 0.28    0.570
    12 months                     1.13 ± 0.38    1.13 ± 0.37    0.99 ± 0.36    0.296

  Outcome                         Genotype       *P*                           
  ------------------------------- -------------- -------------- -------------- -------
  **rs1800797**                                                                
  Constant score (range 0--100)                                                
    Baseline                      37.50 ± 3.98   36.66 ± 3.06   36.56 ± 3.63   0.553
    6 months                      66.05 ± 3.79   66.18 ± 4.11   65.70 ± 3.05   0.916
    12 months                     82.56 ± 3.44   81.62 ± 3.81   81.89 ± 4.18   0.576
  VAS score (range 0--10)                                                      
    Baseline                      6.69 ± 0.50    6.78 ± 0.42    6.70 ± 0.38    0.625
    6 months                      2.65 ± 0.26    2.61 ± 0.33    2.59 ± 0.35    0.770
    12 months                     0.99 ± 0.38    1.15 ± 0.32    1.15 ± 0.47    0.175

Discussion {#sec4}
==========

Findings from the present study suggest that the *IL-6* rs1800795/rs1800797 polymorphisms are associated with an increased risk of RCT. The subgroup analyses performed suggest that the increased effect of rs1800797 polymorphism on RCT is stronger in women, drinkers and subjects with BMI \< 25 kg/m^2^. The *IL-6* rs1800795 polymorphism was correlated with tear size of RCT patients. Additionally, the RCT patients with CG genotype of rs1800795 polymorphism have more obvious surgical treatment effects.

RCT rate increases after the age of 60 \[[@B14]\]. With advancing age, the cuff undergoes several internal changes, such as collagen disorganization and thinning, myxoid and hyaline degeneration, fatty infiltration and vascular proliferation \[[@B15]\]. In addition, the type II collagen variant at the fibrocartilage junctions of the tendon, which is primarily responsible for compressive load, converts into type III \[[@B16]\]. This decreases the capability of the tendon to withstand compressive loads and predisposes it to tear \[[@B16]\]. Moreover, IL-6 and/or soluble IL-6 receptor can down-regulate human type Ⅱ collagen gene expression in articular chondrocytes \[[@B17]\].

The association between *IL-6* rs1800795 polymorphism and disease risk such as cervical cancer \[[@B18]\]; polycystic ovary syndrome \[[@B19]\]; type 2 diabetes \[[@B20]\] and rheumatoid arthritis \[[@B21]\], has been widely investigated. Similarly, *IL-6* rs1800797 polymorphism has also been studied in various disease \[[@B22]\]. However, few studies have investigated its possible association with RCT susceptibility. Patients with full-thickness RCT have greater levels of synovial inflammation compared with controls and IL-6 is significantly increased in individuals with RCT \[[@B7]\]. In the present study, we conducted a hospital-based case--control study to evaluate the role of *IL-6* gene polymorphisms on the risk of RCT. *IL-6* rs1800795 polymorphism conferred susceptibility to RCT and was associated with the tear size. Additionally, we found a significant association between rs1800797 polymorphism and RCT risk, which appeared stronger in women, drinkers and subjects with BMI \< 25 kg/m^2^. To date, the present study represents the first to examine the association between *IL-6* gene variants and RCT risk and may help guide future studies in this area.

Piper et al. \[[@B26]\] conducted a meta-analysis with three Caucasian studies to evaluate operative versus nonoperative treatment for the management of full-thickness RCT. They observed statistically significant differences favoring surgery in both constant and VAS score \[[@B26]\]. The clinical outcome of surgery is significantly better than those of conservative treatment \[[@B26]\], which is similar to our results. Notably, we also evaluate the association between IL-6 gene polymorphisms and constant score and VAS for RCT patients. We found that the constant score of CG genotype of rs1800795 polymorphism significantly improved after 6 months of surgical treatment. Further studies with larger sample size was needed to verify the finding.

There are several limitations to the present study. First, limited availability to the original dataset prevented detection for gene--environment interactions, such as diet and lifestyle. Second, the sample size of the present study was relatively small, as so we cannot rule out the possibility of false-positive or false-negative results. Later, the multicenter studies with larger sample size were need to confirm these findings. Third, two polymorphisms cannot represent the whole *IL-6* gene and may have limited impact on the development of RCT. Lastly, his was a hospital-based case--control study, selection bias was unavoidable and the participants may not represent the whole population.

In conclusion, the *IL-6* rs1800795 or rs1800797 polymorphism showed a statistically significant association with RCT risk, and these polymorphisms may serve as potential biomarkers for early screening and treatment of RCT. Future investigations that include a larger sample size, as well as functional evaluation of the studied polymorphism, are warranted to confirm the findings of the present study.
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